Find Clinical Trials

Inclusion Criteria: 1. 18-75 (inclusive) years old; 2. 18.0 kg/m\^2 ≤ BMI ≤ 35.0 kg/m\^2 and ≥ 50 kg for men and ≥ 45 kg for women at screening; 3. Diagnosis of mild or moderate essential hypertension; 4. Office blood pressure measurements meet any of the following at the time of screening: ① Patients who have not used any antihypertensive medication for at least 4 weeks prior to screening, with an average office sitting blood pressure (average of 3 measurements) of 150 mmHg ≤ SBP \< 180 mmHg and DBP \< 110 mmHg; ② Patients who have been using a stable dose of one or two component of antihypertensive medications (including single agents, two-drug combination or two-component combinations) for at least 4 weeks prior to screening, and who, in the judgment of the clinician, can be switched to levlevamlodipine maleate tablets (2.5 mg/day) or valacyclovir capsules (80 mg/day), and whose mean office sitting blood pressure meets 140 mmHg ≤ SBP \< 180 mmHg and DBP \< 110 mmHg; 5. Prior to randomization, mean office sitting blood pressure meets 140 mmHg ≤ SBP \< 180 mmHg and DBP \< 110 mmHg; 6. Medication adherence between 80% and 120% (including borderline values) during the introductory period. Exclusion Criteria: 1. Rrefractory hypertension, hypertensive emergencies, hypertensive sub-emergencies and secondary hypertension; 2. Allergy (≥ 3 drug or food allergies) or known hypersensitivity to levamlodipine, levlevamlodipine, valsartan and related drugs (dihydropyridine calcium channel blockers, angiotensin II receptor blockers); 3. History of malignancy within the last 5 years (with the exception of cured basal cell carcinoma of the skin, limited squamous cell carcinoma of the skin, or cervical cancer in situ), or an underlying malignancy currently under evaluation; 4. Known or suspected symptomatic upright/postural hypotension ; 5. Uncontrolled diabetes mellitus; 6. Abnormal thyroid function; 7. Severe cardiovascular or cerebrovascular disease within 6 months prior to screening or randomization.

Inclusion Criteria: * The patients who have successfully completed left-sided breast cancer DIBH-IMRT radiotherapy. Exclusion Criteria: * The patients who have not completed left-sided breast cancer DIBH-IMRT radiotherapy.

Inclusion Criteria: * Sign the Informed Consent Form (ICF) before the study, fully understand the contents, process and possible adverse reactions of the study, and be able to follow the contraindications and restrictions specified in this protocol. * Males and females age ≥ 18 years at the time of informed consent. * The pregnancy test for β-human chorionic gonadotropin (hCG) must be negative for women of childbearing potential during the screening period and prior to randomization. * From signing the Informed Consent Form until 3 weeks after the end of treatment, female subjects of childbearing potential and male subjects and their partners must agree to use reliable contraceptive measures and not donate eggs (ova, oocytes) or sperm for assisted reproductive purposes. * According to the diagnostic criteria and classification of diabetes mellitus issued by the World Health Organization (WHO) in 1999, and the supplementary diagnostic criteria recommended by WHO for diagnosis with Hemoglobin A1c (HbA1c) (2011), the time to diagnose T2DM is ≥ 180 days at screening. * Prior to screening, one basal insulin once daily and prandial insulin 2 \~ 4 times daily was given. Or 1 or 2 times daily of a premixed insulin analogue or dual insulin analogue. Exclusion Criteria: * A history of allergy to drugs with two or more mechanisms of action in the past, or known allergies, hypersensitivity, or intolerance to the investigational medicinal product or its excipients (glycerol, phenol, m-cresol, zinc acetate dihydrate, sodium chloride, citric acid monohydrate, or zinc chloride). * Subjects who are pregnant, lactating or planning to become pregnant during the study at screening. * Participated in any drug clinical study (received non-placebo medication during the study) within a recent period of time (90 days or 5 half-lives of the previous investigational medicinal product, whichever is longer), or plans to participate in another clinical study before completing all scheduled assessments in this clinical study. * Underwent invasive cardiovascular or cerebrovascular procedures within 180 days before screening; or experienced acute heart failure, myocardial infarction, stroke, or hospitalization due to angina unstable, transient ischaemic attack, or other acute cardiovascular events within 180 days before screening; or have a history of chronic cardiac failure classified as New York Heart Association Class III or IV at screening; or plan to undergo coronary, carotid, or peripheral arterial revascularisation procedures during the study; or have clinically significant abnormalities on the electrocardiogram (ECG) that require treatment at screening (such as second-degree type II or third-degree atrioventricular block, ventricular fibrillation, ventricular flutter, atrial fibrillation, atrial flutter, Wolff-Parkinson-White syndrome, etc.). * History of malignant tumors before screening (excluding adequately treated or resected non-metastatic basal or squamous cell skin cancer, cervical carcinoma in situ, or prostate cancer in situ) or the presence of underlying malignancy at screening. * The patient with SBP ≥ 160 mmHg or DBP ≥ 100 mmHg during screening. * Subjects who are unable to comply with the requirements of this protocol as judged by the investigator, or have any other conditions that the investigator considers inappropriate to participate in this study.

Inclusion Criteria: * Adults aged ≥50 years; * At least 2 of the following: Prior cardiovascular disease (\>12 months); High cardiovascular risk (SCORE2 or SCORE2 O.P.); Post-stroke (ischemic or hemorrhagic) with treated etiology; Type 2 Diabetes (\> 6 months, ADA); Osteoarthristis (clinical signs/symptoms, NICE); Overweight/Obesity (BMI ≥ 27 kg/m2). * Autonomous walking. * Able to provide informed consent. * Stable medications for ≥ 3 months (related to diagnoses of interest). * Physical activity below WHO recommendations. * No contraindications to exercise (cardiovascular, cerebrovascular, respiratory, musculoskeletal) according to ACSS. Exclusion Criteria: * Moderate to severe cognitive impairment - Montreal Cognitive Assessment (MoCA). * Type 2 Myocardial Infarction. * Class III or IV angina (Canadian Cardiovascular Society). * Class III or IV angina (New York Heart Association). * Uncontrolled CVD: symptomatic arrhythmias with hemodynamic compromise; severe symptomatic aortic valve stenosis; uncontrolled symptomatic heart failure; endocarditis, pericarditis, or active myocarditis; acute aortic syndrome; suspected or known dissecting aneurysm; acute systemic infections. * Pacemaker user. * Neurological disorders affecting gait. * Severe diabetes-related complications contraindicating exercise (poor metabolic control, diabetic foot, diabetic retinopathy, diabetic nephropathy, and diabetic autonomic neuropathy). * Recent use of insulin or sulphonylureas (\< 3 months). * Untreated stroke etiology: indication for revascularization; non-anticoagulated atrial fibrillation; intracranial atherosclerotic occlusive disease. * Musculoskeletal or ocular conditions preventing strength training (acute herniated disc, fractures, recent spinal surgery, glaucoma with elevated intraocular pressure). * Terminal illness. * Inability to understand basic oral or written Portuguese. * Participation in supervised dietary intervention.

Inclusion Criteria: * Age ≥ 18, able to provide informed consent * Patient diagnosed with treatment-resistant depression * Outpatient recommended and approved by psychiatrist for ketamine treatment * Patients who are on IV ketamine and requiring at least 4 treatments of IV ketamine per course (prescribed by their physiatrist) * Cognitively alert, oriented, and able to watch immersive content and respond to questions * Negative human chorionic gonadotropin test before treatment, for female participants of childbearing potential who are not practicing medically appropriate methods of birth control (e.g., hormonal contraceptives, implants, injectables, intrauterine devices, intrauterine systems, etc.) Exclusion Criteria: * History of psychosis/comorbid psychiatric disorders/psychotic depression/dissociative syndromes, significant personality disorder, as clinically assessed by psychiatrist * Using non-prescribed substance (e.g., cannabis) or alcohol use within the preceding 48 hours of treatment * History of substance misuse and/or dependence, including chronic alcohol abuse * Previous ketamine use * Acute dementia/delirium * Acute risk of suicide at baseline, as determined by the study psychiatrist * Pregnancy/breastfeeding * Previous sensitivity to ketamine or related compounds * Unstable medical condition which may require anesthesia consult * History of elevated intracranial pressure or cerebrovascular accident * Recent (within 6 weeks) major cardiovascular event (such as myocardial infarction) * Significant motion sickness (i.e. occur during exposure to physical/visual and virtual motion, cybersickness, etc.) self-identified by patient * Inability to communicate with the study team

Inclusion Criteria: * Left or right hemisphere stroke which has occurred at least 3 months ago * At least mild cognitive deficit and mild aphasia / upper-extremity hemiparesis caused by the stroke * Age 30-80 years * Finnish-speaking (or bilingual, able to participate in Finnish) * Understands the purpose of the study and is able to give informed consent Exclusion Criteria: * Prior significant hearing or visual impairment * Prior severe psychiatric illness (e.g., schizopheria, bipolar disorder, severe unipolar depression) * Prior severe neurological illness (e.g., brain injury, dementia; can have prior TIA or mild stroke)

Inclusion Criteria: 1. Patient with localized breast cancer 2. Patient \> 18 years old 3. Patient requiring chemotherapy +/- combined with immunotherapy or targeted therapy, in neoadjuvant or adjuvant seeting defined by the multidisciplinary consultation meeting. 4. Patient with signed consent 5. Patient has national health insurance coverage Exclusion Criteria: 1. Patient previously treated with chemotherapy for breast cancer 2. Patient with metastatic breast cancer 3. History of psychiatric illness or treatment with neuroleptics, antidepressants or thymoregulators thymoregulator, prior to discovery of cancer (except resolved depressive episode, without psychiatric treatment for at least 2 years). An anxiolytic or hypnotic treatment prescribed after diagnosis is authorized 4. Patient suffering from psychiatric disorders, delusional phases, schizophrenia contraindicating practice of sophrology 5. Patient who has already had an introduction to sophrology in the context of her pathology, or who plans to start sophrology within within 3 months of the start of treatment outside the hospital structure and by her own means 6. Patient does not understand or speak French 7. Cognitive impairment or inability to understand, compromising participation in the study and use and understanding of the device 8. Patient under legal protection, guardianship or trusteeship 9. Inability to undergo protocol monitoring for geographical or social reasons. 10. Patient participating in another interventional study evaluating supportive care

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has locally advanced, non-metastatic (M0), breast cancer, defined as any of the following combined primary tumor (T) and regional lymph node (N) staging per current American Joint Committee on Cancer (AJCC) criteria: cT1c, N1-N2; cT2, N0-N2; cT3, N0-N2; or cT4a-d, N0-N2 * Has centrally confirmed diagnosis of breast cancer that is triple-negative or HR-low+/HER2- breast cancer that will be treated according to the triple-negative breast cancer (TNBC) paradigm * Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load * Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 28 days prior to allocation/randomization * Has left ventricular ejection fraction (LVEF) of ≥50% or ≥ lower limit of normal (LLN) as assessed by echocardiogram (ECHO) or multigate acquisition scan (MUGA) scan Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has uncontrolled or significant cardiovascular disease before randomization * Has any history of or evidence of any current leptomeningeal carcinomatosis. * Has clinically significant corneal disease * Has human immunodeficiency virus (HIV) infection with a history of Kaposi sarcoma and/or multicentric Castleman disease * Has evidence of ongoing, uncontrolled, systemic bacterial, fungal, or viral infection * Has received prior therapy with an anti-programmed death (PD)-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor * Has received any prior treatment, including radiation, systemic therapy, and/or definitive surgery for currently diagnosed breast cancer * Has received prior treatment with an anti-human epidermal growth factor receptor 3 (HER3) antibody and/or antibody-drug conjugate (ADC) that consists of an exatecan derivative that is a topoisomerase I inhibitor (e.g., trastuzumab deruxtecan) * Has metastatic (Stage IV) breast cancer or cN3 nodal involvement * Has known additional malignancy that is progressing or has required active treatment within the past 5 years * Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis * Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, or current or suspected ILD * Has an active infection requiring systemic therapy * Has concurrent active HBV and HCV infection * Has clinically severe respiratory compromise resulting from intercurrent pulmonary illness

Inclusion Criteria: * Adults ≥18 years \< 75years * Diagnosis of PsO or PsA, made by a dermatologist or rheumatologist. * Selected to start secukinumab/ bimekizumab/ Ixekizumab as part of their standard clinical care by their usual dermatology team for PsO or rheumatology clinical team for PsA in line with the license for secukinumab/ bimekizumab/ Ixekizumab and NICE/SMC criteria. * No contraindications to MRI (for example metal fragments or implantable devices not compatible with MRI. (no extra x-ray images will be obtained to check placement of metal fragments or clips insitu. Existing images may be used to check for possible contraindications) * Satisfactory completion of standard pre-biologic safety screening (including, but not limited to, exclusion of latent TB infection according to local protocol, chest X-ray, negative HIV screen, negative Hepatitis screen antibody, negative Hepatitis B surface antigen \[Hep B sAg\] and negative Hepatitis B anti-core antibody \[Hep B cAb\]) * Recent (but not within 4 weeks prior baseline) use of intra-muscular or intra-articular steroid injections * Women of Child-Bearing Potential (WoCBP) must be willing to use effective contraception for study duration. Further information is provided in appendix 1. * Willing to participate and give informed consent Exclusion Criteria: * Inability to provide written informed consent * Severe physical impairment (e.g., blindness, deafness, paraplegia). * Clinically important, active infections e.g. active TB * History of inflammatory bowel disease * Pregnant or breast feeding * Severe claustrophobia precluding MRI * Contraindications to 7T MRI (metal implants in the ears, head or neck, microbladed/ tattooed eyebrows, metal fragments in the eyes) * Confounding neurological disease including MS, Stroke, Traumatic Brain Injury * Previous exposure to IL-17A, IL-17A/F, IL-17R inhibitors or IL-23 p19/p40 inhibitors in the last 6 months * Hypersensitivity to any of the excipients in secukinumab/ bimekizumab/ ixekizumab. * Any reason which, at the investigator's discretion, would make them unsuitable to take part in the study.

INCLUSION CRITERIA For all participants : * Female with age greater than or equal to 18 years For participants with metastatic breast cancer: \- Patient observed with metastatic breast cancer from the outset or metastatic fall from previously treated breast cancer with change of therapeutic line at the time of inclusion. For participants with non-metastatic invasive breast cancer: \- Patient observed with non-metastatic infiltrative breast cancer who had not received any treatment at the time of inclusion (naïve to any treatment) For healthy volunteers: * Participant free of any cancer at the time of inclusion, confirmed using a mammogram whose results must be satisfactory, done at the latest two years before inclusion * Participant with no history of cancer EXCLUSION CRITERIA For all participants: * Male * Age less than 18 years old * Refusal to participate or withdrawal of consent * Pregnant and/or breastfeeding women * Discovery of a cancerous pathology (other than breast cancer for patients) during participant follow-up. For healthy volunteers: * History of cancer * Detection of CTC (positive profile) during screening

Inclusion Criteria: * Patients living with HIV not experienced to ART * Age ≥ 18 years. * eGFR \>60 mL/min * Beneficiaries of the Mexican Social Security Institute treated at the "La Raza" National Medical Center * Patients with a baseline ISI scale score: ≥8-14 points * Patients with a baseline PHQ-9 scale score: 5-9 points * Patients with a baseline HADS-A scale score: 8-10 points * Patients with a baseline HADS-D scale score: 8-10 points * Patients with a baseline Pittsburgh scale score: 5-7 points. Exclusion Criteria: * Patients with use of antidepressants/anxiolytics prior to starting ART * Any Contraindication for the use of second generation INSTI or IP ART regimen * Coinfection with Hepatitis C Virus * Known resistance mutations to any of the components of both treatment regimens.

Inclusion Criteria: 1. Chronic (≥1 year post) SCI of any level or severity 2. 18 years of age or older 3. mild to moderate scores of depression based on the Structured Clinical Interview for DSM-5 (SCID) by clinical psychologist 4. stable dose of depression medications Exclusion Criteria: 1. currently using anti-inflammatory medications 2. variable dosages of depression / anxiety medications 3. currently using anticoagulant medications 4. people with diabetes 5. women who are pregnant or attempting to become pregnant 6. current wound/infection 7. people with suicidal ideation 8. history of eating disorder 9. prior diagnosis of cardiovascular disease

Inclusion Criteria: 1. Diagnosed with metastatic recurrent or unresectable advanced TNBC 2. Documented PD-L1 positivity (SP142 IC ≥ 1) confirmed by local assessment of the most recent tumor sample or an archival tumor sample. 3. In the case of patients who were candidates for curative treatment, the duration from the completion of the curative treatment {date of surgery for primary breast cancer or date of last dose of peri-operative drug therapy (including anthracycline regimen, taxane regimen, anti-PD-(L)1 antibody, capecitabine, poly ADP-ribose polimerase \[PARP\] inhibitors, etc.), whichever is later} to the first local or distant recurrence should be at least 6 months. The date of postoperative radiotherapy is not included in this calculation. The use of anti-PD-(L)1 antibodies is allowed during perioperative drug therapy. 4. ECOG PS 0-1 5. Female or male aged 18 years or older. 6. Histologically or cytologically confirmed TNBC that is ER-negative (\< 10% positive cell occupancy or Allred Proportion score of 0-2), HER2-negative (IHC 1+ or less or FISH/DISH negative) according to ASCO/CAP Criteria 2018 (in the case of IHC2+, negativity is confirmed by FISH/DISH). 7. Patients who have not received chemotherapy for metastatic recurrent or unresectable advanced cancer. However, prior treatment with PARP inhibitors for metastatic recurrent or unresectable advanced cancers in patients with pathogenic BRCA variants is allowed. 8. Having measurable or non-measurable lesions as assessed by local CT or MRI. Tumor lesions located at a previously irradiated site will be considered evaluable if unequivocal progression is seen after radiation. 9. Laboratory tests performed within 14 days before enrollment meet the following criteria \[1\] to \[8\]. However, patients must not have received granulocyte colony-stimulating factor (G-CSF) or blood transfusion within 14 days prior to the date of blood sampling. \[1\] Neutrophil count ≥ 1500/mm3 \[2\] Platelet count ≥ 10 x 104/mm3 \[3\] Hemoglobin ≥ 8.0 g/dL \[4\] AST (GOT) ≤ 100 IU/L (≤ 200 IU/L if liver metastasis is present) \[5\] ALT (GPT) ≤ 100 IU/L(≤ 200 IU/L if liver metastasis is present) \[6\] Total bilirubin ≤ 1.5 mg/dL Total bilirubin \< 3.0 mg/dL for patients with Gilbert's syndrome \[7\] Creatinine ≤ 1.5 mg/dL \[8\] Any of the following criteria is met: i) Urine protein (dipstick) is negative (-) or 1+ ii) If urine protein (dipstick) is ≥ 2+; Measurement of 24-hour urine protein shows urine protein ≤ 1 g/24 hours (may be substituted by urine protein/creatinine ratio ≤ 1) (10) Blood pressure is sufficiently controlled (systolic blood pressure ≤ 150 mmHg and diastolic blood pressure ≤ 90 mmHg with ≤ 2 antihypertensive drugs \[counted as the number of combinations\]). (11) Patients expected to survive for at least 3 months. (12) Written consent has been obtained from the patient himself/herself after sufficient explanation of the contents of the study before registration. (13) In the case of female patients of childbearing potential (including patients who have no menstruation for medical reasons such as chemical menopause), the patients must agree to continue to practice contraception until 5 months after the last dose of atezolizumab or 6 months after the last dose of bevacizumab, nab-PTX or PTX, whichever comes later. Patients must also agree not to breastfeed during study treatment and for at least 5 months after the last dose of atezolizumab and at least 6 months after the last dose of bevacizumab. In the case of male patients with a partner of childbearing potential, the patient whose partner must agree to continue to practice contraception until 6 months after the last administration of PTX and nab-PTX. Exclusion Criteria: 1. Having active brain metastases or carcinomatous meningitis. Previously treated brain metastases are allowed if neurological symptoms have returned to baseline and are clinically stable for at least 2 weeks prior to enrollment. 2. Patients with a history of invasive malignancy within 3 years prior to enrollment. However, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or lesions equivalent to carcinoma in situ or intramucosal carcinoma that are assessed as cured by local treatment are not included in active double cancer. 3. Concurrent or metachronous bilateral invasive breast cancer. However, the patients will be accepted if bilateral lesions are TNBC and are confirmed to be PD-L1-positive by evaluation using a sample of a recurrent lesion. 4. Patients who have received radiotherapy within 14 days prior to enrollment. (Administration or irradiation on the same day of the week 14 days prior to the day of enrollment is permitted.) 5. Patients who have received other study drugs within 14 days prior to enrollment. (Administration on the same day of the week 14 days prior to the day of enrollment is permitted.) 6. Administration of a live vaccine within 30 days of the first dose of the study drug. Administration of inactivated vaccines is permitted. 7. Patients who have received systemic corticosteroid or immunosuppressant equivalent to prednisone exceeding 10 mg/day within 14 days prior to enrollment for active autoimmune disease. (excluding temporary administration for examination or prophylactic administration) 8. Active infection requiring systemic treatment. 9. Patients who concurrently have interstitial lung disease/pneumonitis at the time of enrollment or who have a history of interstitial lung disease/pneumonitis requiring systemic corticosteroids administration. (A history of radiation pneumonitis \[fibrosis\] within the radiation field is permitted.) 10. Patients who are pregnant, possibly pregnant, or lactating. 11. Patients who are positive for HBs antigen or HCV antibody. Patients positive for HCV antibody whose HCV virus level is below the detection limit will be permitted. 12. Patients who are positive for HIV-1 antibody or HIV-2 antibody (test is not essential for enrollment). 13. Patients with significant cardiovascular disease. Patients with a history of myocardial infarction, acute coronary artery disease, coronary angioplasty/stenting/bypass grafting within the last 6 months. Patients with congestive heart failure of Class III to IV of the New York Heart Association. 14. Patients with the following history/concomitant diseases: \[1\] Poorly controlled diabetes mellitus \[2\] Grade ≥ 2 peripheral sensory neuropathy \[3\] Congenital haemorrhagic diathesis/coagulopathy \[4\] Arterial thromboembolism (cerebral infarction, etc.) or venous thromboembolism (deep vein thrombosis, pulmonary embolism, etc.) within 6 months prior to enrollment \[5\] Gastrointestinal perforation, active gastrointestinal ulcer, and Grade ≥ 3 haemorrhage (site not specified) \[6\] Other serious complications (renal failure, hepatic failure, etc.) (15) Patients with a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's completion of the study, or is not in the best interest of the participant to participate in. (16) Patients with any psychiatric condition that may interfere with the conduct of the study. (17) Patients with a history of hypersensitivity to the study drug or its analogues. (18) Patients with alcohol intolerance or a history of hypersensitivity to Cremophor. (19) Patients with a history of active tuberculosis infection.

Inclusion Criteria: * Previously received CBT-GSH at same participating NHS Talking Therapies service * Presenting with anxiety or depression * Deemed suitable for step 2 low-intensity therapy, through assessment by a qualified PWP Exclusion Criteria: * Previously received high-intensity therapy since receiving CBT-GSH * The previous treatment episode was in another NHS Talking Therapies service. * Not fluent in English Individuals who are not fluent in English will be excluded from the study due to not having translated CAT-GSH workbooks available and limited funding to translate any workbooks.

Inclusion Criteria: 1. Age 18-75 years old (including boundary values), male and female. 2. Female subjects weigh ≥45 kg and male subjects weigh ≥50 kg. 3. HRCT shows bronchiectasis affecting one or more lobes of the lung and is confirmed by the clinician as NCFB. 4. The expected survival is greater than 12 months. 5. Informed consent was signed before the trial. 6. Potentially fertile subjects voluntarily take appropriate contraceptive measures. Exclusion Criteria: 1. Patients with pulmonary hypertension or chronic obstructive pulmonary disease (COPD) or asthma as determined by the investigators were the primary diagnosis were screened. 2. An active, symptomatic infection caused by respiratory viruses, including COVID-19, influenza viruses, etc. 3. Have psoriasis or lichen planus. 4. Have Wright's disease/keratosis or hemorrhagic keratosis, or reactive arthritis. 5. Have chlorine acne, large common warts, or keratodermatitis. 6. Has diabetic foot. 7. Have periodontal disease, oral infection, or loose teeth. 8. History of malignant tumor within 5 years prior to screening. 9. Screening subjects with a history of liver disease or currently receiving treatment for liver disease, including but not limited to acute or chronic hepatitis, cirrhosis, or liver failure. 10. Researchers consider any other unstable clinical disease. 11. Oral or inhaled antibiotics were received 4 weeks prior to first administration. 12. Immunosuppressants were administered 4 weeks before the first dose. 13. Received drugs within 4 weeks prior to screening that may cause hyperkeratosis of the skin. 14. Received live attenuated vaccine within 30 days prior to initial administration. 15. Participated in clinical trials of any medical device within 3 months prior to screening. 16. Active hepatitis B virus infection, active hepatitis C virus infection, or known HIV infection or known syphilis infection. 17. Drug abusers. 18. Current smoker or former smoker for less than 3 months. 19. Suspected allergy to the investigational product or any component of the investigational product, or severe allergy to any drug, food, toxin or other exposure. 20. Pregnant or lactating women. 21. The subjects were unable to complete the questionnaires due to their limited educational level, or neither the subjects themselves nor their families could fill in the subject log card. 22. The researchers determined that there were other circumstances that were not suitable for participation in this study.

Inclusion Criteria: Participants must meet all of the inclusion criteria to participate in this study: * Adolescents ages 10-17 years * Diagnosis of mild-to-moderate intellectual disability: ICD-10: F70-F71 and/or diagnosis of developmental disability, including autism: ICD-10: F80-89 * Diagnosis of moderate-to-severe asthma or moderate or severe unspecified asthma: ICD-10: J45.40-J45.909 * Parent/legal guardian is willing to answer questions about their child. * Parent/legal guardian and adolescent must have the ability to understand study procedures and to comply with them for the entire length of the study * English or Spanish-speaking participants * Not involved in other studies using digital inhalers * Males and females of reproductive capability will be enrolled: contraception is not necessary or required. * Participants must use any of the following MDIs (as indicated by the 510(k): Ventolin HFA, ProAir HFA, Advair HFA, Flovent HFA, Xopenex HFA, Symbicort HFA, Atrovent HFA, Proventil HFA, Alvesco HFA, Dulera HFA, and Asmanex HFA. Exclusion Criteria: All candidates meeting any of the exclusion criteria at baseline will be excluded from study participation: * Health status or any clinical conditions: Limited life expectancy, co-existing disease or other characteristics that precludes appropriate diagnosis, treatment, or follow-up in the trial. * Inability or unwillingness of individual or legal guardian/representative to give written informed consent.

Inclusion Criteria: * 1: Age \>18 years old. 2: ASA I-III 3: Patients undergoing elective general anesthesia surgery who are extubated upon arrival to the PACU Exclusion Criteria: * 1: Preoperative comorbidities include severe cardiovascular or respiratory diseases 2: Serious reflux aspiration during the perioperative period 3: Concurrent psychiatric disorders 4: Local skin infections or nerve damage at the upper limb Taiyuan and Hegu acupoints

Inclusion Criteria: 1. Participants who are able to provide written informed consent prior to the initiation of any protocol-required procedures 2. Have been referred to the LEAF clinic by their physician or have self-referred to the LEAF clinic for weight loss, and have been deemed appropriate for weight loss treatment offered by the LEAF clinic (i.e., these criteria are at the discretion of the clinical team at the LEAF clinic, outlined below in the exclusion criteria section). 3. Adults: aged 18-64 years of age (gender and sex will be noted; recruitment is all-gender inclusive). 4. Have a BMI\>30. 5. Have normal or corrected vision as some of the study aspects will involve viewing/responding to visual stimuli. 6. Understand and speak English (as instructions for study criteria will be provided in English). 7. Able to participate in the study protocol as described, e.g. have a means of getting to the laboratories and no major mobility issues to the extent that protocols cannot be followed (details below). 8. Access to a secure internet connection (for virtual appointments with members of the LEAF clinic). Exclusion Criteria: 1. Reporting severe depression or reporting significant suicidal ideation, or history of bipolar disorder or psychosis (i.e., major psychiatric condition; this will be ascertained during the screening carried out by research personnel, in keeping with our standard protocols in Dr. Jaworska's laboratory).\*\*\* 2. Current use of antidepressants, thyroid medication, or any medication that could affect appetite, or seizure threshold (e.g.., bupropion, tamoxifen, thioridazine). 3. Uncontrolled hypertension. 4. History of cardiac defects or symptoms suggestive of any cardiac condition (not including coronary artery disease). 5. Presence of diabetes. 6. Current or past history of addictions or substance use disorder, including undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs. 7. History of eating disorder (including Binge Eating Disorder, Bulimia Nervosa or Anorexia Nervosa). 8. History of glaucoma. 9. Personal or family history of seizure disorders. 10. Currently taking MAO inhibitors (within 14 days), pressor agents, coumadin, anticonvulsants, or phenylbutazone, or other bupropion-containing products (such as Wellbutrin, Wellbutrin SR, Wellbutrin XL, Aplenzin or Zyban), or CYP2B6 inhibitors (e.g. ticlopidine or clopidogrel). 11. History of thyroid disease, chronic liver, or renal disease. 12. Chronic use of opioid, opiate agonist (Methadone) or partial agonists (Buprenorphine). 13. Currently pregnant or planning to become pregnant during the intervention or currently nursing. Pregnancy urine test will be conducted during the in-person screening session in the laboratory.\*\*\* 14. No known allergy to any of the ingredients in CONTRAVE® (e.g. lactose). 15. Hereditary problems of galactose intolerance, lactase deficiency or glucose-galactose malabsorption. 16. Current use of obesity medications such as liraglutide or semaglutide or orlistat. 17. Current use of medication indicated in patient living with ADHD (e.g., Vivanse/Concerta) which are known to have metabolic impacts. There are several additional exclusionary criteria, established by research personnel in Dr. Jaworska's laboratory (i.e., not part of LEAF intake) that preclude participation in the brain imaging/magnetic resonance imaging (MRI) and EEG, these include: 18. Severe claustrophobia. 19. Inability to lie still in the scanner for approximately 30min. 20. Metal in the body that cannot be removed and might pose a safety risk to the participant. 21. History of concussion (loss of consciousness for \>5-min). 22. Major neurological illness, such as, epilepsy, stroke, tumours (as this would interfere with the interpretation of the MRI data). 23. Obesity to the extent that the participant cannot fit into the scanner. This will be established by ensuring that the individual can fit into the mock scanner at the Brain Imaging Centre (BIC) of The Royal. If a person cannot fit into the mock scanner, it is unlikely that the person can fit into the real scanner. 24. Testing positive for illicit drugs and cannabis (this will be established using a drug test that will be administered in the Clinical EEG \& Neuroimaging laboratory at the Institute of Mental Health Research \[IMHR\]). Participants who are cannabis users will be invited to participate in the study so long as they can abstain from cannabis use for approximately 2weeks prior to the baseline session and approximately 2weeks before final assessment. Ideally, participants would also abstain from cannabis use during treatment, but, this will not be tested/enforced. 25. Ability to abstain from nicotine/tobacco and caffeine for 3h prior to the baseline testing/EEG recordings, as both substances influence EEG activity. NOTE: If a participant cannot participate in the MRI aspect of the study (i.e., due to the above exclusion criteria), they will still be able to participate in the research study (apart from the MRI component). All MRI/EEG exclusion criteria will be established during the screening/clinical interview carried out by trained research staff from Dr. Jaworska's laboratory (details below). One final exclusion criterion is as follows: 26. Unable to tolerate the test dose of CONTRAVE® (details below). Such individuals would not participate in further elements of the research, but, would continue with their treatment through the LEAF clinic (as determined by the LEAF clinic, per their clinical management program).

Inclusion Criteria: * Patients with luminal B breast cancer who have undergone the Oncotype DX test at our pathology center, with tissue material available or expected to become available during the enrollment period. * Age ≥ 18 years * Informed consent Exclusion Criteria: none

Inclusion criteria: Patients older than 18 years of age, with pulmonary arterial hypertension (Group 1 PH) and WHO functional class II/III Exclusion:Patients with Inability to walk, wheelchair-bound, amputations, expected survival less than 3 to 6 months, active malignancy patients who are Spanish-speaking. would be excluded from the study.